Showing results (11-20 of 78) with videos related to
Sort By:
Pageof 8
Oncology (Williston Park, N.Y.)|March 27, 2020
The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate CancerAshray Maniar, Amy E Moran, Julie N GraffOncology (Williston Park, N.Y.)|January 12, 2019
Gonadotropin-Releasing Hormone Antagonists in Prostate CancerAdam S Kittai, Jessica Blank, Julie N GraffExpert Opinion on Pharmacotherapy|February 18, 2015
Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancerJulie N Graff, Max J Gordon, Tomasz M BeerUrology|February 5, 2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future researchJulie N Graff, Charles G Drake, Tomasz M BeerFuture Oncology (London, England)|May 28, 2021
KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancerJulie N Graff, Li Wen Liang, Jeri Kim, et al.Clinical Genitourinary Cancer|March 5, 2015
Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer PatientsJulie N Graff, Tomasz M Beer, Bian Liu, et al.Cureus|February 6, 2016
Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine DifferentiationJulie N Graff, George V Thomas, Celestia S Higano, et al.Psycho-Oncology|March 11, 2015
Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and meta-analysisTimothy A Newby, Julie N Graff, Linda K Ganzini, et al.Evaluation Review|June 4, 2010
Contracting for independent evaluation: approaches to an inherent tensionJacob Alex KlermanCancer Immunology Research|May 6, 2014
Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancerJulie N Graff, Sachin Puri, Carlo B Bifulco, et al.Pageof 8